Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 18620939)

1.

Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty.

Mariani S, Giona F, Basciani S, Brama M, Gnessi L.

Lancet. 2008 Jul 12;372(9633):111-2. doi: 10.1016/S0140-6736(08)61023-5. No abstract available.

PMID:
18620939
2.

Trachyonychia in a patient with chronic myeloid leukaemia after imatinib mesylate.

Lau YM, Lam YK, Leung KH, Lin SY.

Hong Kong Med J. 2014 Oct;20(5):464.e2. doi: 10.12809/hkmj134084. No abstract available.

3.

Imatinib mesylate-induced pseudoporphyria in two children.

Mahon C, Purvis D, Laughton S, Bradbeer P, Teague L.

Pediatr Dermatol. 2014 Sep-Oct;31(5):603-7. doi: 10.1111/pde.12380. Epub 2014 Jun 12.

PMID:
24920470
4.
5.

A case of isolated lymphoblastic relapse of the central nervous system in a patient with chronic myelogenous leukemia treated with imatinib.

Park MJ, Park PW, Seo YH, Kim KH, Seo JY, Jeong JH, Kim MJ, Jeong JW, Ahn JY, Park J.

Ann Lab Med. 2014 May;34(3):247-51. doi: 10.3343/alm.2014.34.3.247. Epub 2014 Apr 8. No abstract available.

6.

[Chronic myeloid leukemia treatment and human immunodeficiency virus infection].

Campillo-Recio D, Perez-Rodriguez L, Yebra E, Cervero-Jimenez M.

Rev Clin Esp (Barc). 2014 May;214(4):231-2. doi: 10.1016/j.rce.2014.01.025. Epub 2014 Feb 22. Spanish. No abstract available.

PMID:
24564991
7.

Effectiveness of imatinib therapy for sickle cell anemia and chronic myeloid leukemia.

Murphy M, Close J, Lottenberg R, Rajasekhar A.

Am J Med Sci. 2014 Mar;347(3):254-5. doi: 10.1097/MAJ.0000000000000228. No abstract available.

PMID:
24553361
8.

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.

Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G, Nakaseko C, De Souza CA, Kalaycio ME, Meier S, Fan X, Menssen HD, Larson RA, Hochhaus A.

Blood. 2014 Feb 27;123(9):1353-60. doi: 10.1182/blood-2013-06-510396. Epub 2013 Dec 11.

9.

Multiple eruptive dermatofibromas related to imatinib treatment.

Llamas-Velasco M, Fraga J, Solano-López GE, Steegmann JL, García Diez A, Requena L.

J Eur Acad Dermatol Venereol. 2014 Jul;28(7):979-81. doi: 10.1111/jdv.12328. Epub 2013 Dec 10. No abstract available.

PMID:
24321053
10.

Multiple skin lesions caused by imatinib mesylate treatment of chronic myeloid leukemia.

Machaczka M, Gossart M.

Pol Arch Med Wewn. 2013;123(5):251-2. No abstract available.

11.

Imatinib results in better outcomes than HLA-identical sibling transplants in young persons with newly diagnosed chronic-phase chronic myelogenous leukemia.

Jiang Q, Xu LP, Liu DH, Liu KY, Gale RP, Zhang MJ, Jiang B, Zhang XH, Wang Y, Chen SS, Zhao XY, Chen H, Jiang H, Chen YH, Han W, Qin YZ, Liu YR, Lai YY, Lv M, Huang XJ.

Leukemia. 2013 Dec;27(12):2410-3. doi: 10.1038/leu.2013.159. Epub 2013 May 23. No abstract available.

PMID:
23698276
12.

Periungual pyogenic granuloma following imatinib therapy in a patient with chronic myelogenous leukemia.

Dika E, Barisani A, Vaccari S, Fanti PA, Ismaili A, Patrizi A.

J Drugs Dermatol. 2013 May;12(5):512-3. No abstract available.

PMID:
23652942
13.

Application of comorbidity indexes at baseline could be useful to predict rates of response in patients with chronic myeloid leukemia treated with imatinib.

Breccia M, Salaroli A, Serrao A, Zacheo I, Saracino R, Alimena G.

Leuk Lymphoma. 2014 Jan;55(1):204-6. doi: 10.3109/10428194.2013.795650. Epub 2013 May 29. No abstract available.

PMID:
23586870
14.

Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors.

Berman E, Girotra M, Cheng C, Chanel S, Maki R, Shelat M, Strauss HW, Fleisher M, Heller G, Farooki A.

Leuk Res. 2013 Jul;37(7):790-4. doi: 10.1016/j.leukres.2013.02.005. Epub 2013 Mar 6.

PMID:
23473999
15.

Management of the new patient with CML in chronic phase.

Marin D.

Curr Hematol Malig Rep. 2013 Mar;8(1):37-42. doi: 10.1007/s11899-012-0151-0. Review.

PMID:
23381448
16.

Imatinib-induced Stevens-Johnsons syndrome.

Jha P, Himanshu D, Jain N, Singh AK.

BMJ Case Rep. 2013 Jan 23;2013. pii: bcr2012007926. doi: 10.1136/bcr-2012-007926.

17.

A patient of chronic myelogenous leukemia developing painful rash on feet.

Kumar P, Das NK, Sil A, Chakrabarti P.

J Postgrad Med. 2012 Oct-Dec;58(4):331-4. doi: 10.4103/0022-3859.105489. No abstract available.

18.

Bone metabolism during long-term treatment with imatinib.

O'Sullivan S, Horne A, Wattie D, Porteous F, Gamble G, Browett P, Grey A.

Leuk Lymphoma. 2013 Aug;54(8):1783-5. doi: 10.3109/10428194.2012.760734. Epub 2013 Jan 24. No abstract available.

PMID:
23278638
19.

Vocal fold hemorrhage in a CML patient after Glivec treatment.

Shim HS, Woo SH.

Acta Oncol. 2013 May;52(4):866-8. doi: 10.3109/0284186X.2012.728715. Epub 2012 Nov 15. No abstract available.

PMID:
23153030
20.

Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: evidence for site-specific skeletal effects.

Vandyke K, Fitter S, Drew J, Fukumoto S, Schultz CG, Sims NA, Yeung DT, Hughes TP, Zannettino AC.

J Clin Endocrinol Metab. 2013 Jan;98(1):67-76. doi: 10.1210/jc.2012-2426. Epub 2012 Nov 8.

PMID:
23144472
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk